A foreign manufacturer of Active Pharmaceutical Ingredients (API), excipients, or other pharmaceutical raw materials shipping into Japan is solving a narrower problem than a finished drug or device importer. The receiving side already holds the manufacturing and marketing licenses; what the shipment needs is a compliant customs entry point. This post covers that layer specifically: how an Importer of Record (IOR) structure gets bulk API and pharmaceutical raw-material shipments through Japan Customs (税関) without the foreign supplier standing up a Japan entity, what documentation Japan-side buyers typically expect before they will accept the goods into their licensed supply chain, and where customs classification questions tend to arise for this category of cargo.
Why This Is a Different Problem Than Finished Drug or Device Import
Raw material shipments sit upstream of the two regulatory questions that dominate finished-product import: market authorization and device/drug classification. The Japan-side buyer in an API transaction is, in the ordinary case, a Japan-licensed drug manufacturer or distributor who already holds the Manufacturing License (製造業許可) and, where applicable, Marketing Authorization Holder status (製造販売業者, MAH) under the Pharmaceutical and Medical Device Act (医薬品医療機器等法, commonly PMD Act). That license holder is responsible for the finished drug product placed on the Japan market. The foreign API supplier is not seeking to place a finished product on the market; it is supplying an input into someone else's already-licensed manufacturing process.
This distinguishes the topic from two adjacent questions Aplash addresses elsewhere. Import of a finished medical device, where the importer must resolve both a customs importer question and a device-class approval question before the product can be sold, is a separate problem with its own approval pathway and its own MAH determination. Regulatory affairs and technical staffing questions for pharma and biotech companies operating in Japan are a separate headcount question, not a customs or product question, and do not touch the import declaration at all. Neither of those questions is addressed here. This post is scoped to the customs and import-compliance layer for bulk API and pharmaceutical raw-material shipments only.
What Counts as "Raw Material" for This Purpose
The category covered here includes active pharmaceutical ingredients, pharmaceutical-grade excipients (binders, fillers, coatings, and similar formulation aids), and manufacturing intermediates destined for further processing inside Japan. It does not include finished drug products packaged for retail or clinical dispensing, and it does not include finished medical devices. The distinction matters because the customs treatment, the documentation the receiving party requests, and the point at which PMD Act obligations attach all differ depending on whether the cargo is a raw material feeding a licensed manufacturer or a finished product ready for sale.
PMD Act Touchpoints for Raw Materials Feeding a Japan-Licensed Manufacturer
Raw material import does not require the foreign supplier to obtain its own manufacturing or marketing license in Japan. The compliance burden sits primarily with the receiving Japan-licensed manufacturer, who must be able to demonstrate that every input into a licensed drug product traces to an acceptable source. Two touchpoints recur in practice.
Master File registration for the API itself. Japan operates a registration system commonly referred to as the Drug Master File (原薬等登録原簿), under which the manufacturer of an active ingredient can register manufacturing and quality information with the regulator once, allowing multiple Japan-side drug manufacturers to reference that registration rather than each one separately re-submitting the same underlying data. Whether a given API is already registered, needs registration, or can proceed without it depends on the specific ingredient and the receiving manufacturer's own filing strategy; this is a determination for the receiving license holder and its regulatory affairs function, not something the customs layer resolves.
Traceability to the Japan manufacturer's own license scope. The Japan-licensed manufacturer's Manufacturing License and any associated marketing authorization define what inputs, sources, and specifications it is permitted to use. A raw material shipment that does not match the specification, source, or grade on file with the Japan manufacturer's own registration creates a compliance gap on the receiving side regardless of how cleanly the shipment clears customs. Foreign suppliers should expect the Japan buyer to request specification sheets and source confirmation before, not after, the first shipment, precisely because this traceability obligation sits with the license holder.
The IOR structure does not touch either of these obligations. Appointing an IOR resolves who is the legal importer named on the import declaration (輸入申告); it does not create, substitute for, or satisfy any PMD Act registration or licensing requirement on either the foreign supplier side or the Japan receiving side.
GMP Documentation Foreign Shippers Are Typically Asked For
Japan-licensed manufacturers operate under Good Manufacturing Practice (GMP) requirements that extend to the raw materials entering their facilities. Before accepting a new API or excipient source, the receiving Japan manufacturer will typically request a documentation package to support its own GMP quality system, including:
(a) a Certificate of Analysis (CoA) for the specific batch being shipped, confirming the batch meets the agreed specification;
(b) a GMP certificate or equivalent attestation covering the manufacturing site, issued by the relevant authority in the country of manufacture;
(c) a Certificate of Pharmaceutical Product (CPP), where the receiving party's own registration strategy calls for one;
(d) batch manufacturing records or a summary sufficient to support the receiving manufacturer's own audit trail obligations; and
(e) confirmation of any relevant Master File registration number, where the API is registered under the Drug Master File system described above.
These are documents the Japan-side buyer requests as a condition of accepting the shipment into its own licensed quality system. They are not customs entry documents, and Aplash does not determine what a specific Japan manufacturer requires; that specification comes from the buyer's own quality and regulatory affairs function. What Aplash's IOR engagement can do is confirm, before committing to the import, that the shipment's accompanying paperwork (commercial invoice, packing list, any export-side certificates) is consistent with what the Japan buyer has told its own regulator it will use, so the customs entry and the receiving party's compliance record do not diverge.
Customs Classification Considerations for Pharmaceutical Raw Materials
Pharmaceutical raw materials generally fall within the organic chemicals or pharmaceutical products chapters of the Harmonized System, and which chapter applies typically turns on whether the substance is a defined chemical entity or already a formulated pharmaceutical preparation. Excipients frequently classify outside the pharmaceutical chapters entirely, depending on the underlying chemical or material category. Getting the classification right matters for duty rate, for whether any import consumption tax treatment applies to the specific substance, and for whether the item triggers any additional agency review at the point of entry.
Aplash does not assign HS codes from memory or by analogy to a similar-sounding product. Classification for a specific API, excipient, or intermediate requires the actual chemical composition, CAS number where applicable, and intended use, checked against the current tariff schedule for the correct heading. Any classification claim in this post beyond the general chapter-level distinction above would be speculative; a per-substance classification is a scoped exercise, not a general statement that transfers across ingredients.
How the IOR Structure Interacts With the Receiving Japan-Licensed Manufacturer or Distributor
Under an IOR engagement, Aplash becomes the legal importer named on the import declaration. Aplash purchases the API or raw material shipment from the foreign manufacturer, clears the shipment through Japan Customs in its own name, and re-sells the goods to the Japan-licensed manufacturer or distributor at cost plus duties and import consumption tax pass-through. Aplash issues a qualified invoice (適格請求書), enabling the Japan buyer to recover input Japan Consumption Tax (JCT) on the transaction.
This structure resolves the customs question cleanly, but it does not change who bears PMD Act responsibility for the raw material once it reaches the licensed manufacturer. The Japan-licensed manufacturer or distributor remains responsible for verifying the material against its own Manufacturing License scope, its GMP quality system, and any Master File cross-reference it relies on. An IOR appointment gives the foreign supplier a compliant path to Japan Customs; it does not confer Manufacturing License status, MAH status, or any GMP certification on Aplash, and it does not relieve the Japan receiving party of its own regulatory obligations toward the material it is accepting into its supply chain.
Attorney for Customs Procedures (税関事務管理人, ACP) is the separate structure available to non-resident foreign suppliers that prefer to remain the named importer themselves rather than have Aplash take title. ACP and IOR are structurally distinct and are never presented as alternatives; the ACP mechanism and how consumption tax recovery works under each structure are covered in our dedicated ACP guides.
Where Aplash Fits, and Where It Does Not
Aplash is a regulatory strategy and market-entry firm, not a freight forwarder, logistics provider, or customs broker. On an API or pharmaceutical raw-material shipment, Aplash's role is the IOR structure itself: taking legal title for customs purposes, filing the correct declaration, and coordinating with the Japan-licensed receiving party so the paper trail supports both the customs entry and the receiving party's own quality system. Aplash does not determine PMD Act licensing status, does not perform Master File registration on a manufacturer's behalf, and does not issue GMP certifications. Those determinations sit with the Japan-licensed manufacturer's own regulatory affairs function and the relevant certifying authorities.
For a foreign API manufacturer evaluating a first shipment into Japan, the practical sequence is to confirm the receiving Japan manufacturer's documentation requirements first, get the classification question scoped against the actual substance, and structure the IOR engagement around a shipment that is already aligned with what the Japan buyer's own license permits it to receive. Pricing for an IOR engagement of this kind depends on shipment value, classification complexity, and documentation depth required; contact Aplash directly for a scoped quote rather than relying on a general figure.
This article is informational only and does not constitute legal, tax, or regulatory advice. Consult a qualified advisor before acting on the content. Last updated: 2026-07-18.